Psychopharmacology and Clinical Application of Guanfacine and Clonidine for ADHD – What’s the Difference?

Noradrenaline (NA), also known as norepinephrine, plays a vital role in the pathogenesis of ADHD. Noradrenaline is an important neurotransmitter that – along with dopamine – regulates the Prefrontal Cortex (PFC) cognitive functions. Deficits in PFC function are associated with several features of ADHD, since the prefrontal cortex “keeps in mind” information to help guide a person’s attention and behavior in a thoughtful manner. [Arnsten, 2009]

Three families of adrenergic receptors mediate NA’s effects: α1, α2 and β.

The Cellular Actions of Noradrenaline (NA): [Arnsten, 2009]

• At moderate levels, noradrenaline can improve prefrontal cortex functioning by stimulating postsynaptic α2A receptors.
• NA activation of the α2A receptor strengthens the neuronal signal and hence strengthens network connectivity.
• Higher levels of noradrenaline, however, can impair prefrontal cortex function by stimulating α1 receptors.

Thus, dopamine and noradrenaline have complementary beneficial actions, with noradrenaline increasing the signal and dopamine reducing noise. An optimal balance of both neurotransmitters is required for proper PFC functioning.

Alpha-2 (α2) agonists

The α2 agonists clonidine and guanfacine mimic noradrenaline actions in the PFC through the stimulation of postsynaptic α2 A receptors on PFC neurons. While clonidine stimulates all three receptor subtypes (alpha2A, alpha2B, alpha2C), guanfacine works predominantly on the prefrontal cortex‐2A receptors. [Venables et al., 2017]

Initially developed as a hypertensive agent [Cinnamon Bidwell et al., 2010], clonidine is the generic term for an FDA-approved drug with a wide range of applications. Due to its ability to reduce sympathetic nervous system activity, clonidine leads to a decrease in peripheral resistance, renal vascular resistance, heart rate, and blood pressure. Kapvay is the common brand name for clonidine’s extended-release formulation, while Catapres is the common brand name for clonidine’s immediate-release formulation. 

Medical professionals prescribe clonidine for a range of conditions, such as anxiety, sleep disorders, ADHD, and Tourette’s syndrome. Clonidine is also prescribed to manage drug withdrawal symptoms and treat certain types of pain and behavioral symptoms in psychiatric disorders. Clonidine is available in various forms, including oral tablets and transdermal patches, offering flexibility in dosing and administration.

Clonidine for ADHD

By targeting specific neural pathways, clonidine addresses core ADHD symptoms effectively, making it a critical component of comprehensive ADHD management. Clonidine for ADHD helps improve attention and reduce hyperactivity and impulsivity, and is particularly beneficial for individuals who may not tolerate stimulant medications well or have coexisting conditions such as tic disorders or insomnia.

Kapvay, the trade name for clonidine’s extended-release form, received FDA approval in 2009 for treating ADHD in children and teenagers aged 6 to 17 – either as a standalone therapy or alongside stimulant ADHD drugs. While immediate-release clonidine has not received FDA approval for ADHD treatment, it is occasionally prescribed off-label due to evidence supporting its efficacy in symptom relief. Immediate-release clonidine is generally well-received by adolescents and adults, particularly when administered at bedtime. For younger children, the extended-release version may be preferable, as it releases the drug more gradually to minimize side effects.

Clonidine can be used as a monotherapy or as an adjunct to stimulant medications to enhance ADHD symptom control. While stimulant medication enhances focus and reduces distractibility, alpha-agonists like clonidine for ADHD address impulsivity, emotional regulation, and sleep disorders. 

The specific benefits of clonidine for ADHD include:

• Extended-release clonidine tablets effectively lessen symptoms of ADHD, such as hyperactivity, impulsivity, and inattention, in children aged 6 to 17.
• When combined with stimulant medications, clonidine is shown to diminish aggressive behaviors or conduct issues in children diagnosed with ADHD.
• Adding clonidine to a regimen of stimulant ADHD medications can also improve sleep quality, addressing insomnia symptoms.
• Compared to other ADHD treatments, clonidine can offer symptom relief with a lower incidence of side effects for certain individuals.
• Clonidine carries a minimal risk of abuse or dependency, making it a potentially safer choice for individuals with ADHD who have a history of substance misuse.

Clonidine MOA (Mechanism of Action)

• Presynaptic stimulation of alpha-2 (α-2) receptors reduces the firing of noradrenaline (NA) presynaptic neurons, that release NA into the prefrontal cortex, which improves the impulsive and hyperactive behavior seen in attention-deficit/hyperactivity disorder.
• Adjunctive effects on serotonin and γ-aminobutyric acid receptors also assist in treating insomnia in children with attention-deficit/hyperactivity disorder. Clonidine for sleep disorders in children and adolescents significantly decrease sleep latency and sleep disturbances, improving the quality and quantity of sleep. [Jang et al., 2022]
• Clonidine stimulates postsynaptic α-2 adrenergic receptors and increases noradrenaline signaling to normal levels.
• Clonidine also binds the imidazoline receptors contributing to the hypotensive effect.

Clonidine Dosing Guidelines

• 100-400 mcg /day
• The FDA approved the extended-release version (Kapvay) for monotherapy or adjunctive treatment at doses of 100  mcg-400 mcg /day for children aged 6-17.
• Start with an initial dose of 100 mcg tablet at bedtime
• Daily dosage adjusted in increments of 100 mcg/day at weekly intervals.
• Administered BD (similar to immediate-release). If the dosage is split, give the higher split dosage at bedtime
• Clonidine maximum dose daily is 400 mcg/day.

Clonidine Pharmacokinetics [FDA PI]

• Duration of action of Clonidine IR (immediate-release), such as Catapres, is 6-12 hours.
• Duration of action of Clonidine XR (extended release), such as Kapvay, is 24 hours.

Clonidine Side Effects

• Clonidine side effects are most commonly somnolence, fatigue, bradycardia, and hypotension.
• Heart rate and blood pressure should be measured before initiation of clonidine therapy, following dose increases, and periodically while on clonidine ADHD treatment. Clonidine should be used with caution in patients with a history of hypotension, heart block, bradycardia, or cardiovascular disease because it can decrease blood pressure and heart rate.
• Patients should report the following side effects as soon as possible: allergic reactions such as swelling of the face, tongue, lips or throat; rashes; itching; hives; dizziness; breathing issues; and other unusual reactions.

Guanfacine for ADHD management

Guanfacine modified release – more commonly known as Intuniv for ADHD – is indicated for treating ADHD in children and adolescents aged 6-17. It serves as monotherapy when traditional stimulants or atomoxetine are unsuitable, not tolerated, or ineffective. Additionally, it can be used as adjunctive therapy to psychostimulants when psychostimulants provide a sub-optimal response.

Guanfacine Mechanism of Action

• Guanfacine is a selective α2A-adrenergic receptor agonist with 15-20 times higher affinity for α2A than for the α2B or α2C subtypes. It exhibits therapeutic efficacy with a reduced side effect profile compared to clonidine, enhancing prefrontal cortical functioning leading to behavioral improvement.
• The recommended starting dose for guanfacine is 1 mg once a day.
• Maximum dose 4 mg/day (6-12 years); 7 mg/day (13-17 years) as BD or TDS.
• For adjunctive treatment with stimulants the maximum recommended dose is 4 mg/day.
• Duration of action: 24 hours
• Discontinuation should be gradual to avoid rebound hypertension.

Guanfacine Dosage for ADHD

Guanfacine Modified Release (MR) (Intuniv): [PI]

• The initial dose is 1 mg oral for both monotherapy and when co-administered with psychostimulants.
• The dose is adjusted in increments of no more than 1 mg/week for both monotherapy and when co-administered with psychostimulants.
• The recommended maintenance dose range depending on clinical response and tolerability for Guanfacine MR is 0.05-0.12 mg/kg/day to balance the exposure-related potential benefits and risks. Doses above 4 mg /day are not recommended.
• Guanfacine MR has shown both short term and long-term benefits in treating ADHD.

Guanfacine Pharmacokinetics

Guanfacine Side Effects

• The most common side effects were somnolence, fatigue, bradycardia, and hypotension.
• Heart rate and blood pressure should be measured before initiation of therapy, following dose increases, and periodically while on treatment. Clonidine should be used with caution in patients with a history of hypotension, heart block, bradycardia, or cardiovascular disease because it can decrease blood pressure and heart rate.

• Clonidine is 10 times more potent than guanfacine at α-2 presynaptic receptors, while guanfacine appears more potent at postsynaptic receptors. Activity at postsynaptic alpha-2 receptors translates to enhanced prefrontal cortical regulation of attention and impulse control by strengthening PFC functions. [Strange, 2008]
• Furthermore, guanfacine’s selectivity to the α2A-adrenergic receptor agonist with 15-20 times higher affinity for α2A than for the α2B or α2C subtypes results in therapeutic efficacy with a reduced side effect profile compared to clonidine, enhancing prefrontal cortical functioning leading to behavioural improvement.
• Clonidine also binds to the imidazoline receptors, potentiating the hypotensive effect more than guanfacine.
• The TGA approves Guanfacine MR in Australia for the treatment of ADHD in children and adolescents (6-17)
• Guanfacine modified-release can be administered once daily.
• In Australia, clonidine is not approved for the treatment of ADHD; however, clinically, it is used to manage specific comorbidities in ADHD such as tics [ Joo & Kim, 2018] or insomnia. [Nguyen et al., 2014]

Guanfacine and clonidine are effective agents as monotherapy or augmentation agents in ADHD.

Both clonidine and guanfacine stimulate Alpha-2 adrenergic receptors pre and post-synaptically.

Learn more by watching our video on this topic: Clinical Application of Prazosin & Clonidine – Role of Alpha (α) Adrenergic Receptors (α1 and α2)

Related learning on The Academy

• To build on the psychopharmacology and clinical application of clonidine and guanfacine for ADHD, clinicians may find Advanced Psychopharmacology of ADHD: Medications, Neuroscience and Prescribing Guidelines for Clinicians on The Academy by Psych Scene particularly valuable. The course explores stimulant and non-stimulant ADHD medications, receptor pharmacology, prescribing strategies, and practical approaches to complex ADHD presentations across clinical practice.
• Clinicians seeking a broader understanding of mechanism-based prescribing may also find the Psychopharmacology Masterclass: Advanced Training Series valuable for developing structured approaches to psychopharmacology and complex prescribing considerations.

1. What is the role of clonidine for ADHD?


Clonidine for ADHD is used to reduce hyperactivity, impulsivity, emotional dysregulation, insomnia, and associated behavioural difficulties, particularly when stimulant medications are not well tolerated.

2. How does guanfacine differ from clonidine in ADHD treatment?


Guanfacine is more selective for the α2A receptor, resulting in greater prefrontal cortical specificity and generally fewer sedative and hypotensive effects compared to clonidine.

3. Can clonidine and guanfacine be combined with stimulant medications?


Yes. Both medications may be used as adjunctive therapy alongside stimulants to improve ADHD symptom control, emotional regulation, sleep, and behavioural symptoms.

4. What are the main side effects of clonidine and guanfacine?


Common side effects include sedation, fatigue, hypotension, bradycardia, and dizziness, requiring monitoring of cardiovascular parameters.

5. When might clinicians consider non-stimulant alpha-2 agonists in ADHD?


Alpha-2 agonists may be considered when stimulants are ineffective, poorly tolerated, contraindicated, or when comorbid insomnia, tics, aggression, or emotional dysregulation are prominent.